The European Medicines Agency (EMA) has approved two new biosimilar medications, Afqlir and Opuviz, for the treatment of age-related macular degeneration (ARMD). Both drugs contain aflibercept, the same active ingredient as Eylea, and have comparable quality, safety, and efficacy. They will be administered by qualified physicians experienced in giving injections. Biosimilars are medicines highly similar to approved biological medicines, enabling patient access to safe and effective treatments. However, marketing authorization for Syfovre, an ophthalmic formulation of pegcetacoplan, was refused for treating geographic atrophy secondary to ARMD. The EMA noted that more information on this decision will be published soon.
Source link
Two New Drugs Approved for Age-Related Macular Degeneration
